Renal protective effect and mechanism research of hypoxia inducible factor-1α inhibitor YC-1 in diabetic nephropathy mice

doi:10.3969/j.issn.1674-8115.2023.09.003

Abstract

Abstract:

Objective ·To investigate the effect of hypoxia inducible factor-1α (HIF-1α) inhibitor YC-1 on the progression of diabetic nephropathy (DN) in mice and the potential mechanism. Methods ·Ten-week-old male db/db mice (DN model) and their nondiabetic wild-type (WT) littermates were divided into 4 groups (n=6) according to whether treated with YC-1 or not: WT group, WT+YC-1 group, DB group, and DB+YC-1 group. The treatment groups were intraperitoneally injected with YC-1 (20 mg·kg^-1) once a day, while the non-treatment groups received the same volumes of DMSO injection. After a total of 8 weeks of intervention, blood glucose, body weight, and kidney weight of all mice were measured. Serum, urine and kidney tissue samples were harvested. Serum creatinine, urinary albumin-to-creatinine ratio (UACR), and urine neutropil gelatinase-associated lipocalin (NGAL) levels were detected. The kidneys were stained with ?hemat?oxyli?n-eosin (H-E) and periodic acid-Schiff (PAS) to observe the pathological changes. Masson staining was used to detect fibrosis, collagen-Ⅰ was detected by immunohistochemistry, and α-smooth muscle actin (α-SMA) was detected by Western blotting. The expression of HIF-1α was detected by both Western blotting and immunohistochemistry. TUNEL staining and Western blotting for apoptosis-related proteins were used to observe the cell apoptosis level. Superoxide dismutase (SOD) activity and malondialdehyde (MDA) level were detected by the kits. Endoplasmic reticulum stress (ERS) markers, including immunoglobulin heavy chain binding protein (BiP, also known as GRP78), phospho-protein kinase R-like endoplasmic reticulum kinase (p-PERK), total PERK, phospho-eukaryotic initiation factor 2α (p-eIF2α), total eIF2α, activating transcription factor 4 (ATF4), and C/EBP homologous protein (CHOP), were determined by Western blotting. Results ·Compared with the WT group, the DB group showed significant rise of blood glucose, loss of renal function, severe kidney histopathology injuries and kidney fibrosis, increase of renal HIF-1α expression, and aggravated oxidative stress and ERS. Whilst there were no significant changes in blood glucose, YC-1 treatment notably reduced kidney weight/body weight ratio, serum creatinine, UACR, and urine NGAL levels in db/db mice. YC-1 treatment ameliorated kidney histopathology injuries and kidney fibrosis, and decreased the expressions of collagen-Ⅰ and α-SMA. YC-1 treatment also reduced the number of TUNEL positive cells, the expression of HIF-1α and pro-apoptotic proteins including BAX and cleaved caspase-3, and MDA level in the kidneys of db/db mice, while promoting anti-apoptotic protein BCL-2 expression and SOD activity. The expressions of ERS markers GRP78, p-PERK, p-eIF2α, ATF4, and CHOP were likewise significantly decreased in DB+YC-1 group. Conclusion ·HIF-1α inhibitor YC-1 inhibits oxidative stress and abnormal activation of ERS, improving cell apoptosis and fibrosis in the kidneys of DN mice, which would attenuate the aggravation of pathological damage and loss of kidney function.

Key words: diabetic nephropathy (DN), hypoxia inducible factor-1α (HIF-1α), oxidative stress, endoplasmic reticulum stress (ERS)

CLC Number:

R587.2

JIA Junjie, XING Haifan, ZHANG Qunzi, LIU Qiye, WANG Niansong, FAN Ying. Renal protective effect and mechanism research of hypoxia inducible factor-1α inhibitor YC-1 in diabetic nephropathy mice[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(9): 1089-1098.

Figures/Tables 7

TrendMD

References 28

1	GUEDES M, PECOITS-FILHO R. Can we cure diabetic kidney disease? Present and future perspectives from a nephrologist′s point of view[J]. J Intern Med, 2022, 291(2): 165-180.
2	JUNG C Y, YOO T H. Pathophysiologic mechanisms and potential biomarkers in diabetic kidney disease[J]. Diabetes Metab J, 2022, 46(2): 181-197.
3	HESP A C, SCHAUB J A, PRASAD P V, et al. The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?[J]. Kidney Int, 2020, 98(3): 579-589.
4	SEMENZA G L. Oxygen sensing, homeostasis, and disease[J]. N Engl J Med, 2011, 365(6): 537-547.
5	LIU H X, LI Y J, XIONG J. The role of hypoxia-inducible factor-1 α in renal disease[J]. Molecules, 2022, 27(21): 7318.
6	OUYANG C L, ZHANG J, LEI X Y, et al. Advances in antitumor research of HIF-1α inhibitor YC-1 and its derivatives[J]. Bioorg Chem, 2023, 133: 106400.
7	KHANIJOU V, ZAFARI N, COUGHLAN M T, et al. Review of potential biomarkers of inflammation and kidney injury in diabetic kidney disease[J]. Diabetes Metab Res Rev, 2022, 38(6): e3556.
8	CHEN P, SHI X Z, XU X J, et al. Liraglutide ameliorates early renal injury by the activation of renal FoxO1 in a type 2 diabetic kidney disease rat model[J]. Diabetes Res Clin Pract, 2018, 137: 173-182.
9	ZHANG Q Z, HE L, DONG Y, et al. Sitagliptin ameliorates renal tubular injury in diabetic kidney disease via STAT3-dependent mitochondrial homeostasis through SDF-1α/CXCR4 pathway[J]. FASEB J, 2020, 34(6): 7500-7519.
10	NI L H, YUAN C, WU X Y. Endoplasmic reticulum stress in diabetic nephrology: regulation, pathological role, and therapeutic potential[J]. Oxid Med Cell Longev, 2021, 2021: 7277966.
11	NANGAKU M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure[J]. J Am Soc Nephrol, 2006, 17(1): 17-25.
12	SHU S Q, WANG Y, ZHENG M L, et al. Hypoxia and hypoxia-inducible factors in kidney injury and repair[J]. Cells, 2019, 8(3): 207.
13	STANIGUT A M, PANA C, ENCIU M, et al. Hypoxia-inducible factors and diabetic kidney disease-how deep can we go?[J]. Int J Mol Sci, 2022, 23(18): 10413.
14	ZHANG H, XU R F, WANG Z C. Contribution of oxidative stress to HIF-1-mediated profibrotic changes during the kidney damage[J]. Oxid Med Cell Longev, 2021, 2021: 6114132.
15	HU J P, WANG W L, ZHANG F, et al. Hypoxia inducible factor-1α mediates the profibrotic effect of albumin in renal tubular cells[J]. Sci Rep, 2017, 7(1): 15878.
16	MEI S Q, LI L, ZHOU X J, et al. Susceptibility of renal fibrosis in diabetes: role of hypoxia inducible factor-1[J]. FASEB J, 2022, 36(8): e22477.
17	JIA Y J, CHEN J Q, ZHENG Z K, et al. Tubular epithelial cell-derived extracellular vesicles induce macrophage glycolysis by stabilizing HIF-1α in diabetic kidney disease[J]. Mol Med, 2022, 28(1): 95.
18	LI X Y, YANG S S, YAN M H, et al. Interstitial HIF1A induces an estimated glomerular filtration rate decline through potentiating renal fibrosis in diabetic nephropathy[J]. Life Sci, 2020, 241: 117109.
19	NAYAK B K, SHANMUGASUNDARAM K, FRIEDRICHS W E, et al. HIF-1 mediates renal fibrosis in OVE26 type 1 diabetic mice[J]. Diabetes, 2016, 65(5): 1387-1397.
20	PACKER M. Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics[J]. Am J Kidney Dis, 2021, 77(2): 280-286.
21	IACOBINI C, VITALE M, HAXHI J, et al. Mutual regulation between redox and hypoxia-inducible factors in cardiovascular and renal complications of diabetes[J]. Antioxidants (Basel), 2022, 11(11): 2183.
22	DIEBOLD I, PETRY A, HESS J, et al. The NADPH oxidase subunit NOX4 is a new target gene of the hypoxia-inducible factor-1[J]. Mol Biol Cell, 2010, 21(12): 2087-2096.
23	HETZ C, ZHANG K Z, KAUFMAN R J. Mechanisms, regulation and functions of the unfolded protein response[J]. Nat Rev Mol Cell Biol, 2020, 21(8): 421-438.
24	MOULIN S, THOMAS A, WAGNER S, et al. Intermittent hypoxia-induced cardiomyocyte death is mediated by HIF-1 dependent MAM disruption[J]. Antioxidants (Basel), 2022, 11(8): 1462.
25	YANG Y Y, YU H H, JIAO X L, et al. Angiopoietin-like proteins 8 knockout reduces intermittent hypoxia-induced vascular remodeling in a murine model of obstructive sleep apnea[J]. Biochem Pharmacol, 2021, 186: 114502.
26	DELBREL E, SOUMARE A, NAGUEZ A, et al. HIF-1α triggers ER stress and CHOP-mediated apoptosis in alveolar epithelial cells, a key event in pulmonary fibrosis[J]. Sci Rep, 2018, 8(1): 17939.
27	SUN F Q, DU J C, LI H B, et al. FABP4 inhibitor BMS309403 protects against hypoxia-induced H9c2 cardiomyocyte apoptosis through attenuating endoplasmic reticulum stress[J]. J Cell Mol Med, 2020, 24(19): 11188-11197.
28	MOULIN S, THOMAS A, ARNAUD C, et al. Cooperation between hypoxia-inducible factor 1α and activating transcription factor 4 in sleep apnea-mediated myocardial injury[J]. Can J Cardiol, 2020, 36(6): 936-940.

Index	WT group	WT+YC-1 group	DB group	DB+YC-1 group
RBG/(mmol·L^-1)	8.10±0.39	8.25±0.43	28.57±1.18^①	29.15±1.29^①
BW/g	27.47±0.58	25.98±0.65	56.72±1.05^①	54.53±1.02^①
KW/BW/(mg·g^-1)	9.97±0.23	10.19±0.23	12.25±0.22^①	11.31±0.14^①②
Scr/(mg·dL^-1)	0.239±0.010	0.263±0.012	0.473±0.017^①	0.414±0.016^①③
UACR/(μg·mg^-1)	61.68±12.18	67.46±10.71	1 445.61±63.10^①	663.94±60.19^①②
uNGAL/(μg·mL^-1)	23.70±1.09	23.04±0.95	118.66±2.98^①	86.02±3.44^①②

Index	WT group	WT+YC-1 group	DB group	DB+YC-1 group
RBG/(mmol·L^-1)	8.10±0.39	8.25±0.43	28.57±1.18^①	29.15±1.29^①
BW/g	27.47±0.58	25.98±0.65	56.72±1.05^①	54.53±1.02^①
KW/BW/(mg·g^-1)	9.97±0.23	10.19±0.23	12.25±0.22^①	11.31±0.14^①②
Scr/(mg·dL^-1)	0.239±0.010	0.263±0.012	0.473±0.017^①	0.414±0.016^①③
UACR/(μg·mg^-1)	61.68±12.18	67.46±10.71	1 445.61±63.10^①	663.94±60.19^①②
uNGAL/(μg·mL^-1)	23.70±1.09	23.04±0.95	118.66±2.98^①	86.02±3.44^①②

Index	WT group	WT+YC-1 group	DB group	DB+YC-1 group
MDA level/(nmol·mg^-1)	6.69±0.53	5.78±0.82	14.05±1.56^①	9.65±0.71^②
SOD activity/(U·mg^-1)	117.28±11.90	115.29±6.72	41.71±3.19^①	79.40±2.52^③

Index	WT group	WT+YC-1 group	DB group	DB+YC-1 group
MDA level/(nmol·mg^-1)	6.69±0.53	5.78±0.82	14.05±1.56^①	9.65±0.71^②
SOD activity/(U·mg^-1)	117.28±11.90	115.29±6.72	41.71±3.19^①	79.40±2.52^③

[1]	WANG Liyang, XUE Wei. Research progress on the role of oxidative stress in the development of diabetic bladder dysfunction [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(2): 241-246.
[2]	CHEN Minghao, LIU Peiyu, WANG Xuan, WU Yixiang, JIANG Yujin, ZHANG Chaoyang, ZHANG Jingfa. Advances in drug therapy of diabetic retinopathy [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(7): 822-829.
[3]	ZENG Dejie, CHEN Zenghui, DING Qiankun, SUN Xiaqing, SUN Qi, ZHAO Shibing. Prospect of naturally derived polysaccharides in intervention in neurodevelopmental disorders [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(6): 779-787.
[4]	WANG Ying, PING Lifeng, LIU Tongtong, LIU Shanshan, LIU Lei. Effect of neferine on diabetic nephropathy by regulating SDF-1/CXCR4 signal pathway [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(2): 183-195.
[5]	JIN Fangquan, FAN Chenghu, TANG Xiaodong, CHEN Yantong, QI Bingxian. Research progress in the relationship between mitochondrial dysfunction and osteoporosis [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(6): 761-767.
[6]	LU Ruoyu, KANG Wenhui, ZHAO Anda, LU Zhaohui, LI Shenghui. Research progress on the association between melatonin and hypertensive disorder complicating pregnancy [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(10): 1297-1303.
[7]	WU Jiajin, ZHONG Chen, LI Dawei, CHEN Ruoyang, QU Junwen, ZHANG Ming. Role of methyltransferase like 3 regulating pri-miR-21 methylation in renal fibrosis of diabetes nephropathy [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(1): 1-7.
[8]	ZHAO Jiuhong, TONG Jiating, SHEN Zhijun, LÜ Yehui. Research progress in the mechanism of interactive regulation between circular RNA and oxidative stress [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(3): 393-399.
[9]	SUN Jinli, SONG Weiwei, XU Ming, LI Jingquan. Oxidative damage and malignant migration of hepatocellular carcinoma cells LM3 induced by 14 weeks exposure to sodium arsenite [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(12): 1677-1684.
[10]	Jiu-ang MAO, Zhen WENG, Xiao-yin NIU, Yang HE, Zhen-xin WANG. Role of Tmprss6 gene in radiation-induced intestinal injury of mice [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(9): 1175-1182.
[11]	Sheng CHEN, Zhi-long YAN, Ye-ming WU, Min XU, Song GU, Jing MA. Expression and clinical significance of HIF-1α/SHH signaling pathway in neuroblastoma [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1056-1061.
[12]	Run-ze YANG, Wen-ning XU, Huo-liang ZHENG, Sheng-dan JIANG. Effects of exosomes derived from human umbilical vein endothelial cells on apoptosis of pre-chondrogenic cells stimulated by inflammatory factors [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(2): 147-153.
[13]	Jing WU, Xue-yi LI, Jing-hong CHEN, Ze-jian WANG. Study on changes of hippocampal bile acid receptors in the depression mouse models [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(12): 1628-1634.
[14]	LU Hai-yang, ZHAO Wei-li. Role of gastrointestinal microbiota in tumorigenesis [J]. , 2019, 39(9): 1083-.
[15]	YANG Shuang-shuang1, GAO Tian-xing2, HE Xuan1, ZHANG Rui1, ZHANG Yong-fang1. Regulation on brain-derived neurotrophic factor and relevant mechanism of anemarrhena saponin in H2O2-induced SH-SY5Y cells [J]. , 2019, 39(6): 578-.